Inclusion Criteria:

          1. Patients must be ≥18.

          2. For the Part 1 Dose-Escalation Phase, patients must be diagnosed with the following:

               1. Relapsed or refractory AML with myelomonocytic or monoblastic/monocytic
                  differentiation according to the World Health Organization 2016 criteria and has
                  failed treatment with available therapies known to be active for AML.

               2. Relapsed or refractory CMML and has failed treatment with available therapies
                  known to be active for CMML

          3. Part 2 Expansion Phase:

             a) Relapsed or refractory AML with myelomonocytic or monoblastic/monocytic
             differentiation and has failed treatment with available therapies known to be active
             for AML.

          4. Patients must be amenable to serial BM aspirates/biopsies and peripheral blood
             sampling during the study.

          5. Patients must be able to understand and willing to sign an informed consent. A legally
             authorized representative may consent on behalf of a patient who is otherwise unable
             to provide informed consent, if acceptable to and approved by the site and/or site's
             Institutional Review Board (IRB) or Ethics Committee.

          6. Patients must have an ECOG performance status of 0 to 2

          7. Patients must have adequate hepatic function

          8. Patients must have adequate renal function

          9. Patients must be recovered from any clinically relevant toxic effects of any prior
             surgery, radiotherapy, or other therapy intended for the treatment of cancer (patients
             with residual Grade 1 toxicity, or any grade of alopecia, are allowed; patients with
             peripheral neuropathy that is not more than Grade 2 and stable are allowed).

         10. Patients must be off systemic calcineurin inhibitors (e.g., cyclosporine, tacrolimus)
             for at least 4 weeks prior to study drug treatment.

         11. Female patients with reproductive potential must have a negative serum pregnancy test
             within 7 days prior to the start of therapy.

        Exclusion Criteria:

          1. Patients who have previously received IO-202.

          2. Patients who have undergone HSCT within 60 days of the first dose of IO-202, or
             patients on immunosuppressive therapy post human stem cell transplantation (HSCT) at
             the time of screening, or with clinically significant graft-versus-host disease (GVHD)
             (the use of a stable dose of oral steroids post-HSCT of <10 mg prednisone/day or dose
             equivalent of other corticosteroid and/or topical steroids for ongoing skin GVHD is
             permitted with Medical Monitor approval).

          3. Patients who received systemic anti-cancer therapy or radiotherapy <7 days prior to
             their first day of study drug administration (Hydroxyurea or leukapheresis is allowed
             up to 24 hours prior to the first dose. However, hydroxyurea must be ceased 24 hours
             prior to the first dose of IO-202 treatment in Cycle 1); it may be initiated again if
             necessary 24 hours after the first dose of IO-202 treatment in Cycle 1).

          4. Patients who received an investigational agent <7 days prior to their first day of
             study drug administration. In addition, the first dose of IO-202 should not occur
             before a period ≥5 half-lives of the investigational agent has elapsed.

          5. Patients for whom potentially curative anti-cancer therapy is available.

          6. Patients who are pregnant or breast feeding.

          7. Patients with uncontrolled, active infection.

          8. Patients with known hypersensitivity to any of the components of the IO-202
             formulation.

          9. Active known malignancy with the exception of any of the following:

               1. Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or
                  in situ cervical cancer;

               2. Low-risk prostate cancer for which observation or hormonal therapy only is
                  indicated;

               3. Any other malignancy treated with curative intent with the last treatment
                  completed ≥6 months before study initiation (with the exception of hormonal
                  therapies when indicated).

         10. Patients with New York Heart Association (NYHA) Class III or IV congestive heart
             failure (CHF) or left ventricular ejection fraction (LVEF) <40% by echocardiogram
             (ECHO) or multi-gated acquisition (MUGA) scan ≤28 days prior to Cycle 1, Day 1.

         11. Any of the following in the previous 6 months: myocardial infarction, congenital long
             QT syndrome, Torsades de pointes, clinically significant arrhythmias (including
             sustained ventricular tachyarrhythmia and ventricular fibrillation), and left anterior
             hemiblock (bifascicular block), unstable angina, coronary/peripheral artery bypass
             graft, symptomatic CHF (NYHA class III or IV), cerebrovascular accident, transient
             ischemic attack, or pulmonary embolism. Patients with asymptomatic right bundle branch
             block or controlled atrial fibrillation are allowed.

         12. Ongoing cardiac dysrhythmias Grade 2 or higher per of NCI CTCAE, Version 5.0, Grade
             ≥2.

         13. Known or suspected hypersensitivity to recombinant human proteins.

         14. Known active bacterial, viral, and/or fungal infection including hepatitis B (HBV),
             hepatitis C, human immunodeficiency virus (HIV), acquired immunodeficiency syndrome
             (AIDS)-related illness, or active Covid-19 infection. . Hepatitis B and C and HIV
             testing are not required for asymptomatic patients; however, for patients who have
             previously tested positive or have a known history of hepatitis B and C, HIV, and/or
             tuberculosis, clinical laboratory assessments at screening will include repeat testing
             for the previous infection. A sample for SARS-CoV-2 should be obtained during the
             screening period, and results must be available prior to C1D1.

         15. Patients with any psychological, familial, sociological, or geographical condition
             potentially hampering compliance with the study protocol and follow-up schedule; those
             conditions should be discussed with the patient before trial entry.

         16. Patients with clinical signs and/or symptoms suggesting active, uncontrolled central
             nervous system (CNS) leukemia or known active, uncontrolled CNS leukemia (a lumbar
             puncture is not required in patients without signs or symptoms that are suggestive of
             CNS leukemia). Note: Patients with controlled CNS leukemia (documented by 2
             consecutive assessments of zero blast count in cerebrospinal fluid), and who are still
             receiving intrathecal (IT) therapy at study entry are considered eligible and will
             continue to receive IT therapy.

         17. Patients with immediately life-threatening, severe complications of leukemia such as
             uncontrolled bleeding, pneumonia with hypoxia or shock, or disseminated intravascular
             coagulation.

         18. Donor Lymphocyte Infusion within 30 days prior to first IO-202 administration.

         19. Current active treatment in another interventional therapeutic clinical study.

         20. Chronic systemic corticosteroid treatment with a dose of ≥10 mg prednisone/day or dose
             equivalent of another corticosteroid. Topical applications, inhaled sprays, eye drops,
             local injections of corticosteroids, and systemic steroids required for acute medical
             interventions are allowed.

         21. Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results and, in the judgment of the Investigator, would make the patient
             inappropriate for entry into this study.

         22. Acute Promyelocytic Leukemia patients or patients with known Philadelphia chromosome
             (Ph+) positive AML or chronic myelogenous leukemia (CML) blast crisis.

         23. Hyperleukocytosis (leukocytes ≥25 x 10e9/L) at first dose of IO-202. These patients
             may be treated with hydroxyurea or receive leukapheresis treatment according to
             routine practice, and enrolled in the study when the leukocyte count falls below 25 x
             10e9/L.

         24. Patients who are investigational site staff members or relatives of those site staff
             members or patients who are Immune-Onc employees directly involved in the conduct of
             the trial.